An analysis of final 2021 DAWN data presents: (1) nationally representative weighted estimates, including percent and unadjusted rates per 100,000, for all drug-related ED visits, (2) nationally representative weighted estimates for the top five drugs in drug-related ED visits, (3) the assessment of monthly trends and drugs involved in polysubstance...
Search Results
Preliminary Findings from Drug-Related Emergency Department Visits, 2021. An analysis of 2021 preliminary data presents (1) nationally representative weighted estimates for the top five drugs in drug-related ED visits, (2) the assessment of monthly trends and drugs involved in polysubstance ED visits in a subset of sentinel hospitals, and (3)...
This report presents an evaluation of the coverage, overlap, biases, strengths, and weaknesses of three sources of data on the receipt of specialty substance use treatment: the National Survey on Drug Use and Health (NSDUH), the National Survey of Substance Abuse Treatment Services (N-SSATS), and the Treatment Episode Data Set...
This Drug Abuse Warning Network (DAWN) short report shows the estimated number of emergency room visits involving buprenorphine between 2005 and 2011. Buprenorphine is used to treat dependence on heroin and narcotic pain medications. The report also shows buprenorphine-related visits broken out by non-medical use, adverse reactions and seeking detoxification...
This Drug Abuse Warning Network (DAWN) report shows emergency room visits in 2010 involving synthetic cannabinoid products commonly called \"Spice\" or \"K2\". These drugs are also known as synthetic marijuana,
This Drug Abuse Warning Network (DAWN) short report shows the estimated number of emergency department visits involving phencyclidine (PCP) between 2005 and 2011. The report specifically talks about age groups, gender and other drugs such as marijuana, cocaine, heroin and pharmaceuticals and trends over time.